Mechanism Study to Investigate Difference in Efficacy of Neoadjuvant Chemoimmunotherapy in Lung Squamous Cell Carcinoma

Launched by TANG-DU HOSPITAL · May 28, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a treatment approach for patients with lung squamous cell carcinoma (LUSC), which is a type of lung cancer. The study aims to understand why some patients do not respond well to immunotherapy, a treatment that helps the immune system fight cancer. Specifically, the trial will explore changes in the tumor environment before and after a combination treatment of immunotherapy and chemotherapy. Participants will receive three cycles of a specific immunotherapy along with two chemotherapy drugs.

To be eligible for the trial, participants should be between 40 and 80 years old and have a confirmed diagnosis of operable locally advanced LUSC, meaning their cancer can still be surgically removed. They should not have received any previous anti-cancer treatments. Participants will also need to provide tissue samples taken before treatment. It’s important to note that individuals with certain conditions, such as brain metastases or specific lung diseases, are not eligible. Those who join can expect to contribute to valuable research that could improve future treatments for lung cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. aged 40 to 80 years;
• • 2. had histologically confirmed LUSC with operable locally advanced stage
• • 3. no prior anti-tumor therapy; received neoadjuvant immunotherapy consisting of three cycles of anti-PD-1 ICB plus nab-paclitaxel and carboplatin
• • 4. pre-treatment tissues
• Exclusion Criteria:
• • 1. the presence of central nervous system metastases
• • 2. the presence of immunodeficiency disease; previous therapies with immunosuppressants within 14 days prior to the initiation of study treatment;
• • 3. uncontrolled hypertension
• • 4. history of or having pulmonary fibrosis or interstitial lung disease